A stapled peptide inhibitor (RSM3) disrupted the METTL3-METTL14 protein complex, triggered METTL3 degradation, and significantly suppressed tumor growth in two mouse models.
Significant tumor suppression in 2 modelsStapled peptide RSM3 reduced tumor growth and enhanced cancer cell death while degrading the METTL3 oncogene in vivo
What the researchers found
From candidate peptides screened against the METTL3-METTL14 binding interface, RM3 showed the highest anti-cancer potency by both inhibiting METTL3 activity and promoting its proteasomal degradation. The stapled version (RSM3) had enhanced stability and maintained the α-helical structure needed for METTL3 interaction.
In two in vivo tumor models, RSM3 treatment significantly suppressed tumor growth and enhanced apoptosis. Mechanistically, RSM3 increased METTL3 degradation, reduced global RNA m6A methylation levels, upregulated programmed cell death genes, and inhibited cancer-promoting signaling pathways. This dual mechanism — complex disruption plus protein degradation — distinguishes it from competitive small-molecule inhibitors.
Why it matters
METTL3 is increasingly recognized as an oncogene across multiple cancer types, but therapeutic options targeting it are limited. This study introduces a fundamentally different approach — using a stapled peptide to disrupt a protein-protein interaction rather than competing at the enzyme's active site. The dual mechanism of enzyme inhibition plus degradation could provide more complete suppression of METTL3 activity.
How the study worked
Researchers designed peptides targeting the METTL3-METTL14 protein-protein interaction interface. The lead peptide RM3 was optimized into a stapled version (RSM3) for improved stability and helical structure. Activity was assessed through in vitro enzyme inhibition assays, cell-based cancer models, and transcriptomic analysis. In vivo efficacy was tested in two mouse tumor models, with measurements of tumor growth, apoptosis, METTL3 protein levels, and global RNA methylation.
What this study cannot tell us
The study was conducted in cell lines and mouse tumor models, which may not fully predict human responses. Pharmacokinetics, biodistribution, and potential off-target effects of RSM3 in humans are unknown. The specific cancer types tested were not detailed in the abstract, and generalizability to other METTL3-driven cancers needs investigation. Long-term safety of disrupting RNA methylation was not assessed.
How to read the evidence
This is a preclinical study with in vitro and in vivo (mouse) data. While the results are promising and include animal tumor models, no human testing has been performed. This represents early-stage evidence for a novel therapeutic approach.
When this study was published
Published in 2024, this is very recent research at the cutting edge of stapled peptide therapeutics and RNA methylation-based cancer biology.
The bigger picture
Stapled peptides are an emerging class of therapeutics that combine the specificity of peptides with improved stability and cell penetration. This study demonstrates their potential in targeting protein-protein interactions in the RNA modification machinery — a rapidly growing area of cancer biology. As the role of m6A RNA methylation in cancer becomes clearer, tools like RSM3 could lead to new therapeutic strategies.
Questions still open
- Which specific cancer types would be most responsive to METTL3-targeted stapled peptide therapy?
- What are the potential side effects of reducing global RNA m6A methylation in normal tissues?
- Can RSM3 be combined with existing cancer immunotherapies or chemotherapies for enhanced efficacy?
Common questions
What is a stapled peptide and why does it matter for cancer treatment?
What does METTL3 do in cancer?
Read the original research
A Stapled Peptide Inhibitor Targeting the Binding Interface of N6-Adenosine-Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy.
Angewandte Chemie (International ed. in English), 63(24), e202402611
Citation
Li, Zenghui; Feng, Yuqing; Han, Hong; Jiang, Xingyue; Chen, Weiyu; Ma, Xuezhen; Mei, Yang; Yuan, Dan; Zhang, Dingxiao; Shi, Junfeng. (2024). A Stapled Peptide Inhibitor Targeting the Binding Interface of N6-Adenosine-Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy.. Angewandte Chemie (International ed. in English), 63(24), e202402611. https://doi.org/10.1002/anie.202402611